abstract_id,session_title,abstract_title,ground_truth,default_model_extraction_response,default_model_validation_response,default_model_primary_drugs,default_model_secondary_drugs,default_model_comparator_drugs,default_model_removed_drugs,default_model_reasoning,default_model_success,default_model_llm_calls,default_model_verification_response,default_model_verification_results,default_model_verification_removed_drugs
6022,,"A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma",,"```json
{
""Primary Drugs"": [
""Polatuzumab Vedotin"",
""Rituximab"",
""Cyclophosphamide"",
""Doxorubicin"",
""Prednisone"",
""Orelabrutinib"",
""Chidamide"",
""Venetoclax"",
""Lenalidomide"",
""Penpulimab""
],
""Secondary Drugs"": [],
""Comparator Drugs"": [
""RCHOP-X"",
""Pola-Rchp""
],
""Reasoning"": [
""1. Identified the main experimental arm and the comparator arms using the keyword 'Versus'."",
""2. Extracted the individual drugs from the main experimental arm: Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab."",
""3. Classified all these individual drugs as 'Primary Drugs' based on the connecting keywords 'and' and 'Combined with'."",
""4. Excluded the regimen abbreviation 'Pola-RCHP-X' because its full constituent drugs were provided, following the exclusion rules."",
""5. Identified 'RCHOP-X' and 'Pola-Rchp' as the comparator arms."",
""6. Classified the abbreviated regimens 'RCHOP-X' and 'Pola-Rchp' as 'Comparator Drugs' as their expanded forms were not listed in the title."",
""7. Confirmed no secondary drugs were mentioned based on the absence of relevant keywords."",
""8. Formatted the final JSON output according to the specified rules.""
]
}
```","```json
{
  ""Primary Drugs"": [
    ""Polatuzumab Vedotin"",
    ""Rituximab"",
    ""Cyclophosphamide"",
    ""Doxorubicin"",
    ""Prednisone"",
    ""Orelabrutinib"",
    ""Chidamide"",
    ""Venetoclax"",
    ""Lenalidomide"",
    ""Penpulimab""
  ],
  ""Secondary Drugs"": [],
  ""Comparator Drugs"": [
    ""RCHOP-X"",
    ""Pola-Rchp""
  ],
  ""Removed Drugs"": [],
  ""Reasoning"": [
    ""1. Normalized the title by trimming whitespace and identifying connectors such as 'combined with', slashes '/', and 'versus' to separate regimens and individual drugs (confidence: high)."",
    ""2. Verified that all extracted Primary Drugs (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Orelabrutinib, Chidamide, Venetoclax, Lenalidomide, Penpulimab) appear literally in the title as components of the experimental combination (confidence: high)."",
    ""3. Confirmed that 'RCHOP-X' and 'Pola-Rchp' appear literally in the title as named comparator regimens in the 'Versus RCHOP-X and Pola-Rchp' clause, indicating they are therapeutic comparators (confidence: high)."",
    ""4. Scanned the title for other capitalized or short tokens (e.g., 'Pola-RCHP-X', 'Diffuse', 'Large', 'B-Cell') and determined that only 'Pola-RCHP-X' is a regimen acronym already represented by its component drugs, while the others are disease descriptors or non-drug terms (confidence: high)."",
    ""5. Applied non-drug pattern checks and confirmed that no extracted item is a trial identifier, endpoint, biomarker/gene, institution, or device; all are known anticancer agents or regimen names used therapeutically in lymphoma (confidence: high)."",
    ""6. Treated 'RCHOP-X' and 'Pola-Rchp' as regimen comparators because the title explicitly compares 'Pola-RCHP-X' versus these regimens, and their internal components are not fully spelled out here; thus they are correctly classified under Comparator Drugs (confidence: high)."",
    ""7. Noted that 'Pola-RCHP-X' itself is not listed in the extracted JSON; this is acceptable because its constituent drugs are explicitly enumerated and captured as Primary Drugs, so the acronym need not be included separately (confidence: high)."",
    ""8. Determined that there are no separate supportive, background, or prior therapies designated as secondary; all mentioned agents are part of randomized treatment arms, so Secondary Drugs remains empty (confidence: high)."",
    ""9. Since all extracted items are valid therapeutic agents or regimens within the study arms and no spurious tokens were identified, no items were placed in Removed Drugs (confidence: high)."",
    ""10. Performed final QC to ensure correct categorization, title case formatting, and compliance with the required JSON structure (confidence: high).""
  ]
}
```","[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone"", ""Orelabrutinib"", ""Chidamide"", ""Venetoclax"", ""Lenalidomide"", ""Penpulimab""]",[],"[""RCHOP-X"", ""Pola-Rchp""]",[],"[""1. Normalized the title by trimming whitespace and identifying connectors such as 'combined with', slashes '/', and 'versus' to separate regimens and individual drugs (confidence: high)."", ""2. Verified that all extracted Primary Drugs (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Orelabrutinib, Chidamide, Venetoclax, Lenalidomide, Penpulimab) appear literally in the title as components of the experimental combination (confidence: high)."", ""3. Confirmed that 'RCHOP-X' and 'Pola-Rchp' appear literally in the title as named comparator regimens in the 'Versus RCHOP-X and Pola-Rchp' clause, indicating they are therapeutic comparators (confidence: high)."", ""4. Scanned the title for other capitalized or short tokens (e.g., 'Pola-RCHP-X', 'Diffuse', 'Large', 'B-Cell') and determined that only 'Pola-RCHP-X' is a regimen acronym already represented by its component drugs, while the others are disease descriptors or non-drug terms (confidence: high)."", ""5. Applied non-drug pattern checks and confirmed that no extracted item is a trial identifier, endpoint, biomarker/gene, institution, or device; all are known anticancer agents or regimen names used therapeutically in lymphoma (confidence: high)."", ""6. Treated 'RCHOP-X' and 'Pola-Rchp' as regimen comparators because the title explicitly compares 'Pola-RCHP-X' versus these regimens, and their internal components are not fully spelled out here; thus they are correctly classified under Comparator Drugs (confidence: high)."", ""7. Noted that 'Pola-RCHP-X' itself is not listed in the extracted JSON; this is acceptable because its constituent drugs are explicitly enumerated and captured as Primary Drugs, so the acronym need not be included separately (confidence: high)."", ""8. Determined that there are no separate supportive, background, or prior therapies designated as secondary; all mentioned agents are part of randomized treatment arms, so Secondary Drugs remains empty (confidence: high)."", ""9. Since all extracted items are valid therapeutic agents or regimens within the study arms and no spurious tokens were identified, no items were placed in Removed Drugs (confidence: high)."", ""10. Performed final QC to ensure correct categorization, title case formatting, and compliance with the required JSON structure (confidence: high).""]",True,2,"{
  ""Primary Drugs"": [
    ""Polatuzumab Vedotin"",
    ""Rituximab"",
    ""Cyclophosphamide"",
    ""Doxorubicin"",
    ""Prednisone"",
    ""Orelabrutinib"",
    ""Chidamide"",
    ""Venetoclax"",
    ""Lenalidomide"",
    ""Penpulimab""
  ],
  ""Secondary Drugs"": [],
  ""Comparator Drugs"": [
    ""RCHOP-X"",
    ""Pola-Rchp""
  ],
  ""Removed Drugs"": [],
  ""Reasoning"": [
    ""1. Normalized the title by trimming whitespace and identifying connectors such as 'combined with', slashes '/', and 'versus' to separate regimens and individual drugs (confidence: high)."",
    ""2. Verified that all extracted Primary Drugs (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Orelabrutinib, Chidamide, Venetoclax, Lenalidomide, Penpulimab) appear literally in the title as components of the experimental combination (confidence: high)."",
    ""3. Confirmed that 'RCHOP-X' and 'Pola-Rchp' appear literally in the title as named comparator regimens in the 'Versus RCHOP-X and Pola-Rchp' clause, indicating they are therapeutic comparators (confidence: high)."",
    ""4. Scanned the title for other capitalized or short tokens (e.g., 'Pola-RCHP-X', 'Diffuse', 'Large', 'B-Cell') and determined that only 'Pola-RCHP-X' is a regimen acronym already represented by its component drugs, while the others are disease descriptors or non-drug terms (confidence: high)."",
    ""5. Applied non-drug pattern checks and confirmed that no extracted item is a trial identifier, endpoint, biomarker/gene, institution, or device; all are known anticancer agents or regimen names used therapeutically in lymphoma (confidence: high)."",
    ""6. Treated 'RCHOP-X' and 'Pola-Rchp' as regimen comparators because the title explicitly compares 'Pola-RCHP-X' versus these regimens, and their internal components are not fully spelled out here; thus they are correctly classified under Comparator Drugs (confidence: high)."",
    ""7. Noted that 'Pola-RCHP-X' itself is not listed in the extracted JSON; this is acceptable because its constituent drugs are explicitly enumerated and captured as Primary Drugs, so the acronym need not be included separately (confidence: high)."",
    ""8. Determined that there are no separate supportive, background, or prior therapies designated as secondary; all mentioned agents are part of randomized treatment arms, so Secondary Drugs remains empty (confidence: high)."",
    ""9. Since all extracted items are valid therapeutic agents or regimens within the study arms and no spurious tokens were identified, no items were placed in Removed Drugs (confidence: high)."",
    ""10. Performed final QC to ensure correct categorization, title case formatting, and compliance with the required JSON structure (confidence: high).""
  ]
}",{},[]
